Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion
- 1 January 2004
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (1) , 83-88
- https://doi.org/10.1177/0091270003261343
Abstract
The objective of this study was to evaluate the absolute bioavailability and acute pharmacokinetics of treprostinil sodium administered by continuous, short-term subcutaneous infusion in normal subjects. Fifteen healthy volunteers received treprostinil via an intravenous infusion at 15 ng/kg/min over 150 minutes, followed by a 5- to 7-day washout and a subcutaneous infusion at the same rate administered over 150 minutes. Serial plasma samples were collected predosing, during dosing, and postdosing, and plasma treprostinil concentration levels were measured by a validated liquid chromatography atmospheric pressure ionization tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 25 pg/mL. Acute administration of treprostinil administered by subcutaneous infusion at a rate of 15 ng/kg/min for 150 minutes achieved a mean Cmax of 1.47 ng/mL. Mean AUC infinity values for intravenous and subcutaneous dosing were 3.52 and 3.97 ng.h/mL, respectively, resulting in a mean apparent absolute bioavailability of 113% for subcutaneous administration. It was possible that the area under of the curve for the intravenous administration was underestimated because most of the terminal elimination phase could not be documented due to the LLOQ of the assay. The mean apparent elimination half-life of treprostinil following subcutaneous administration was 1.38 hours, compared to 0.87 hours following intravenous administration. It was concluded that treprostinil administered by subcutaneous administration is completely absorbed, with a slightly longer half-life compared to intravenously administered treprostinil.Keywords
This publication has 10 references indexed in Scilit:
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case SeriesAnnals of Internal Medicine, 1999
- Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart DefectsCirculation, 1999
- Treatment of pulmonary hypertension secondary to connective tissue diseasesThorax, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dogProstaglandins, Leukotrienes & Essential Fatty Acids, 1993
- Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous cathetersThe American Journal of Medicine, 1991
- The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogsProstaglandins, Leukotrienes & Essential Fatty Acids, 1991